Arvinas Trades at Its Cash — and Prices the First-Approved PROTAC at Zero

Arvinas's market cap sits around $609 million. On June 30 the company held $567.9 million in cash and marketable securities. Put the two numbers side by side and the market is pricing everything else Arvinas owns — an approved breast-cancer drug plus a five-asset pipeline — at roughly $40 million.

That is a strange place for a biotech that just made history. In May the FDA approved vepdegestrant, sold as VEPPANU, the first-ever PROTAC: a drug that works by tagging disease-causing proteins so the cell's own disposal machinery chews them up, a mechanism that stayed theory for decades. The milestone didn't produce a launch. Days later Arvinas and its partner Pfizer handed global rights to the drug to Rigel Pharmaceuticals for an $85 million upfront split between them, up to $320 million in milestones, and tiered royalties in the mid-teens to mid-20s on sales.

The handoff is the whole story. A biotech that finally won approval for a first-in-class drug earned the right to be judged as a commercial business — and chose to become a royalty receiver plus an early-stage pipeline instead. The market noticed, and it wrote the stock down about 20% year to date; even the August pop from the licensing quarter faded.

Start with the second-quarter economics, because they make the position explicit. Arvinas reported $249.7 million of revenue in the quarter ended June 30 — but nearly all of it was one-time. Roughly $112.6 million was Pfizer collaboration revenue (much of it deferred revenue recognized on the Rigel deal), $62.5 million was the Rigel license itself, and $50 million was a milestone paid on approval. Earnings swung to $2.58 a share. None of that is recurring product revenue, and the market treated it that way.

Why the market is skeptical deserves respect, because the reason runs deeper than a cheap multiple. The approval's supporting study, VERITAC-2, showed vepdegestrant improved median progression-free survival by just 2.9 months versus the standard fulvestrant — and only in the patients whose tumors carry an ESR1 mutation. That is a narrow label and a modest edge. The truest tell is the deal: when the first PROTAC was finally approved, neither Arvinas nor Pfizer wanted to launch it themselves. They brought in a commercial partner. Management framed it as focus; it also reads as a drug with a limited commercial ceiling.

Now the discount's other side. For that ~$40 million over cash, an investor receives the royalty on an approved drug, roughly two years of runway, and a bet on the pipeline. The cash funds operations into the second half of 2028, and three Phase 1 readouts are due within twelve months: ARV-393 (a BCL6 degrader for lymphoma) in the second half of 2026, biomarker data from ARV-102 (a LRRK2 degrader for Parkinson's) in October 2026, and muscle-degradation data from ARV-027 in the first half of 2027. If even one shows real activity, a $40 million price for the whole non-cash company starts to look cheap.

This is not a fallen stock to buy because the sentiment will revert. The caution is earned: every asset left is Phase 1, and Phase 1 drugs fail most of the time. The floor is the cash, and there is not much margin above it — management bought back about $92 million of stock last year, a signal that it trusts its own pipeline, but one that ate into the cushion. The net-cash valuation is defensible; it reflects a real discount on an unproven pipeline.

The context that frames the bet: Kymera, the other big name in targeted protein degradation, trades near a $9.75 billion market cap — roughly sixteen times Arvinas. The platform is not out of favor; the market has simply decided that Arvinas's specific assets are worth little until proven. One of those two judgments is wrong.

So the case reduces to a named condition, not a narrative. Pay roughly $40 million over cash for a call on three Phase 1 readouts in the next year, plus a royalty on the first approved PROTAC, with the downside floored by cash and about two years of runway to decide. The investor-conference circuit is noise; the data is the variable. If the readouts fail, the cash is the value and it burns down to second-half-2028. If they hit, the market will be forced to admit that forty million was one of the cheapest asks in biotech.